The dRVVT Confirm (dilute Russell's Viper Venom Test Confirm) measures the presence of lupus anticoagulants (LA), autoantibodies linked to clotting disorders and antiphospholipid syndrome (APS). It compares screening and confirmatory test phases, with a normal ratio (0.8–1.2) indicating no significant LA interference. Elevated ratios (>1.2) suggest LA presence and possible increased clotting risk, while low ratios (<0.8) are rare and usually not clinically relevant. This test is vital for diagnosing APS and evaluating unexplained blood clots or recurrent pregnancy loss, providing key insights for managing autoimmune or clotting conditions.

Dilute Russell's viper venom time (dRVVT) is a laboratory test often used for detection of lupus anticoagulant (LA). Russell's viper venom [RVV] isolated from the snake Daboia russelii contains a potent activator of factor X which in the presence of phospholipid, prothrombin and calcium ions clots fibrinogen to fibrin. In individuals with a lupus anticoagulant the antibody binds to the phospholipid inhibiting the action of the RVV and prolonging the clotting time. 

The dRVVT Screen Ratio is a key component of lupus anticoagulant (LA) testing. It is calculated from the dilute Russell's viper venom time (dRVVT) screen test, which uses a low-phospholipid reagent to increase sensitivity to lupus anticoagulant. A normal dRVVT screen ratio is typically less than 1.20, while an elevated ratio (≥1.20) may suggest the presence of LA. However, elevated results can also arise from coagulation factor deficiencies, anticoagulant medications, or other inhibitors.

The screen ratio is determined by dividing the patient’s plasma clotting time by the clotting time of normal pooled plasma. When the ratio is elevated, additional tests, such as mixing studies and confirmatory assays, are often performed to distinguish lupus anticoagulant from other causes of prolonged clotting times.

Evaluating patients with signs and symptoms consistent with systemic lupus erythematosus (SLE).

The anti-double stranded DNA (anti-dsDNA) tests are used to help diagnose and monitor lupus, also called systemic lupus erythematosus or SLE, a chronic inflammatory autoimmune disorder in which the immune system mistakenly targets the body’s own cells and tissues.

The "Dust Mite (Dermatophagoides pteronyssinus) IgE" test measures your body's immune response to a common allergen found in household dust mites. Dust mites, tiny creatures invisible to the naked eye, thrive in warm, humid environments like bedding, carpets, and furniture. When you inhale or come into contact with dust containing these mites, your immune system may react by producing specific antibodies called IgE (Immunoglobulin E) if you’re sensitive to them.

Biomarkers:

- IAD/Methane Score

- PP Bacteria/Yeast

- Reference Variance

- Total Abundance

Therapeutic Support Options: 

Therapeutic support options are static to serve as potential treatment ideas. Clinician discretion is advised when selecting appropriate therapeutics for individual patients.

- Pre-/Probiotics

- Increase Dietary Fiber Intake

- Consider SIBO Testing

- Increase Resistant Starches

- Increase Fermented Foods

- Meal Timing

Genova’s data analysis has led to the development of unique dysbiosis patterns, related to key physiologic disruptions, such as immunosuppression and inflammation. These patterns may represent dysbiotic changes that could pose clinical significance. 

Ehrlichia chaffeensis antibody (IgG) testing is a critical diagnostic tool used to detect previous or ongoing infections with Ehrlichia chaffeensis, the bacterium responsible for human monocytic ehrlichiosis (HME), a potentially severe tick-borne disease.

The presence of IgG antibodies against E. chaffeensis in a patient's blood suggests an immune response to this specific pathogen. IgG antibodies are typically produced later in the course of an infection and can persist for a long period, often indicating past exposure or a more chronic form of the infection. In clinical settings, testing for E. chaffeensis IgG is particularly important for patients presenting with symptoms suggestive of HME, which include fever, headache, malaise, and sometimes more severe manifestations like thrombocytopenia, leukopenia, and elevated liver enzymes.

The E. Chaffeensis Ab IgG test is a specialized diagnostic tool pivotal in the field of infectious diseases, particularly in the context of tick-borne illnesses. Ehrlichia chaffeensis is the bacterium responsible for Ehrlichiosis, a condition transmitted through tick bites, primarily in regions where ticks are endemic. The IgG antibody test for E. chaffeensis plays a crucial role in the diagnosis and management of this infection.

Ehrlichia chaffeensis Ab (IgM) testing plays a critical role in the early diagnosis of human monocytic ehrlichiosis (HME), a tick-borne illness caused by the bacterium Ehrlichia chaffeensis. This test specifically looks for IgM antibodies, which are among the first antibodies produced by the immune system in response to an infection. The presence of IgM antibodies against E. chaffeensis typically indicates a recent or ongoing infection, as these antibodies usually develop within the first week or two after exposure to the bacterium and can be detected before the IgG antibodies.

The E. Chaffeensis Ab IgM test is a crucial diagnostic tool in the realm of infectious diseases, specifically for the timely detection of Ehrlichiosis, a tick-borne illness caused by the Ehrlichia chaffeensis bacterium. This test detects IgM antibodies, which are among the first antibodies produced by the immune system in response to an infection.

The Etiocholanolone/Androsterone (E/A) Ratio assesses androgen metabolism by comparing the enzymatic activity of 5b-reductase/5a-reductase. Etiocholanolone is produced via the 5b-reductase pathway and androsterone is produced via the 5a-reductase pathway.

The Etiocholanolone/Androsterone (E/A) Ratio assesses androgen metabolism by comparing the enzymatic activity of 5β-reductase/5α-reductase.